Aidoc vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aidoc is an AI radiology platform with FDA-cleared algorithms that detect and flag critical findings in medical scans, helping radiologists prioritize urgent cases.
About
Aidoc is an Israeli-American AI medical imaging company founded in 2016 that has built a comprehensive AI radiology platform with the largest portfolio of FDA-cleared imaging algorithms in the market. The platform integrates with radiology workflow systems to automatically analyze incoming scans, detect critical findings across multiple conditions, and prioritize worklists so radiologists review the most urgent cases first rather than working strictly in order of arrival. Aidoc's algorithms cover a broad range of conditions across multiple anatomical regions including intracranial hemorrhage, pulmonary embolism, incidental pulmonary nodules, and spine fractures. The company raised over $140M and is deployed at over 1,000 healthcare sites worldwide. Aidoc's aiOS platform enables third-party AI algorithms to run alongside its own models, creating an open ecosystem for AI in radiology. The company serves radiology departments seeking to improve throughput, reduce missed findings, and support radiologists managing increasing imaging volumes. Aidoc positions its platform as an AI operating system for radiology rather than a collection of point solutions, enabling comprehensive AI coverage across an entire radiology practice.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.